Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CUE |
---|---|---|
09:32 ET | 2417 | 0.4751 |
09:41 ET | 2500 | 0.461194 |
09:45 ET | 200 | 0.462 |
09:50 ET | 220 | 0.460001 |
09:54 ET | 100 | 0.46 |
09:59 ET | 632 | 0.4749 |
10:03 ET | 691 | 0.4706 |
10:06 ET | 300 | 0.48 |
10:15 ET | 100 | 0.4706 |
10:24 ET | 350 | 0.4775 |
10:32 ET | 100 | 0.4706 |
10:46 ET | 100 | 0.4702 |
10:48 ET | 1000 | 0.471 |
10:53 ET | 1913 | 0.4702 |
10:55 ET | 3056 | 0.4649 |
11:02 ET | 100 | 0.4649 |
11:20 ET | 100 | 0.465 |
11:24 ET | 7966 | 0.4618 |
11:26 ET | 6273 | 0.4698 |
11:27 ET | 817 | 0.4648 |
11:29 ET | 240 | 0.465 |
11:31 ET | 598 | 0.4603 |
11:33 ET | 899 | 0.4611 |
11:36 ET | 500 | 0.4698 |
11:40 ET | 500 | 0.4613 |
11:44 ET | 725 | 0.4614 |
12:00 ET | 100 | 0.465 |
12:03 ET | 100 | 0.4662 |
12:05 ET | 1000 | 0.4689 |
12:14 ET | 1500 | 0.4688 |
12:23 ET | 100 | 0.4634 |
12:36 ET | 800 | 0.466151 |
12:43 ET | 17857 | 0.4667 |
12:48 ET | 500 | 0.464 |
12:56 ET | 664 | 0.47 |
12:57 ET | 1117 | 0.4635 |
01:01 ET | 200 | 0.46675 |
01:10 ET | 100 | 0.4635 |
01:14 ET | 320 | 0.4635 |
01:39 ET | 200 | 0.4699 |
01:42 ET | 600 | 0.4698 |
01:44 ET | 2101 | 0.46555 |
01:51 ET | 360 | 0.46555 |
01:53 ET | 500 | 0.4612 |
01:55 ET | 600 | 0.4612 |
02:00 ET | 1400 | 0.4655 |
02:02 ET | 150 | 0.4612 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cue Biopharma Inc | 23.1M | -0.5x | --- |
Evogene Ltd | 12.7M | -0.6x | --- |
Palatin Technologies Inc | 15.5M | -0.4x | --- |
COSCIENS Biopharma Inc | 15.5M | -0.4x | --- |
Marker Therapeutics Inc | 23.0M | -2.4x | --- |
Kineta Inc | 7.4M | -0.3x | --- |
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $23.1M |
---|---|
Revenue (TTM) | $8.3M |
Shares Outstanding | 48.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.95 |
EPS | $-0.97 |
Book Value | $0.79 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 2.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -582.23% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.